ReviewNature reviews. Immunology2007
Siglecs and their roles in the immune system.
Review in Nature reviews. Immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,089 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,089 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,995 citations in OpenAlex.
- Genetic Biomarkers for Periodontal Diseases: A Systematic Review.Journal of clinical periodontology · 2025Pooled it
- Druggable genome-wide Mendelian randomization identifies therapeutic targets for metabolic dysfunction-associated steatotic liver disease.Lipids in health and disease · 2025Pooled it
- Add-OnNutrients · 2024Trial
- Review
- Innate immune response to Streptococcus suis infection: advances and future challenges.Veterinary research · 2026Review
- Mismatch Repair-Proficient Colorectal Cancer Can Evade Immune Surveillance through an Intrinsic Suppressive Program.Cancer discovery · 2026Article
- TAMing the tumor: targeting immune inhibitory receptors on tumor-associated macrophages in pediatric brain tumors - an emerging immunotherapy strategy.Journal for immunotherapy of cancer · 2026Review
- SIGLEC12 Predicts Prognosis and Chemotherapeutic Vulnerability in Patients with Pancreatic Cancer.Annals of surgical oncology · 2026Article
- Realizing the potential of agonistic antibody immunotherapy.Nature reviews. Drug discovery · 2026Review
- From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chemical reviews · 2026Review
- Impact of sialyltransferase deletion in mature T cells on control of subcutaneous and metastatic cancers.Glycobiology · 2026Article
- Persistent cytolytic CD8Cell reports. Medicine · 2026Article
- The microenvironment dictates glyco-immune surveillance via HSF1-mediated metabolism.Science advances · 2026Article
- Siglec-1 expression and localization in the male reproductive tract of the dromedary camel during the rutting season.Tropical animal health and production · 2026Article
- ABHD17C-Mediated S-Depalmitoylation of BCL6B Enhances CD24 Transcription to Resist Macrophage Phagocytosis in Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle.Materials today. Bio · 2026Review
- Spatial transcriptomics maps distinct signatures of human intermuscular adipose expansion in mice.medRxiv : the preprint server for health sciences · 2026Article
- Apoptotic bodies in bone homeostasis and skeletal disease: biology and therapeutic implications.Apoptosis : an international journal on programmed cell death · 2026Review
- Prediction of Novel Disease-Related Regions in SIGLEC-7 byInternational journal of molecular sciences · 2026Article
- CD22 as a Target for Hematological Malignancies and Autoimmune Diseases.International journal of molecular sciences · 2026Review
1,029 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell surfaces in the immune system are richly equipped with a complex mixture of glycans, which can be recognized by diverse glycan-binding proteins. The Siglecs are a family of sialic-acid-binding immunoglobulin-like lectins that are thought to promote cell-cell interactions and regulate the functions of cells in the innate and adaptive immune systems through glycan recognition. In this Review, we describe recent studies on signalling mechanisms and discuss the potential role of Siglecs in triggering endocytosis and in pathogen recognition. Finally, we discuss the postulated functions of the recently discovered CD33-related Siglecs and consider the factors that seem to be driving their rapid evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.